Seems to me the final ratio will be somewhere near

Seems to me the final ratio will be somewhere near 300 to 132 due to ongoing enrollment in the open label extension, with all new folks getting leronlimab.
300 to 132 = 2.27 to 1

(1 or 2 of the 391 to 394th get placebo and 1 or 2 get leronlimab)
(Then, a bunch more getting leronlimab join in under the open label extension)

I almost gave up getting any info about the Winston-Salem, NC trial site. I was thinking that if I, my wife, or a friend got the virus, then we may go there.
Finally, I found some info. The person said I cannot be admitted based upon data from my hospital locally. I would have to travel (in severe/critical condition) to Novant Hospital in Winston-Salem, NC, be admitted as a patient, and then I would be evaluated for possible admission to the trial to get leronlimab.

Seems s/c patients are better off hoping to get leronlimab under the eIND program. When m/m, I will request invermectin per (Dr Yo and others and recent studies) and a steroid.

Some are predicting a very high % of Americans will get covid-19 by April/May/June when the vaccines are been widely administered and have produced immunity. Like, you and me are likely to become infected. We should each be making plans for m/m intervention and s/c intervention.

Similar situation, when leronlimab is approved, there will be a limited supply and thus a prioritizing as to who gets it first. And leronlimab may cure me, but 2 weeks later I could get infected again. Well... then hopefully I get more leronlimab again and the share price goes up a little more, a double dip.